Akanda Corp.
Akanda Corp. (AKAN) Stock Competitors & Peer Comparison
See (AKAN) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AKAN | $4.36 | +15.31% | 9.9M | -1.39 | -$3.14 | N/A |
| ZTS | $154.79 | -0.26% | 68.6B | 26.65 | $5.81 | +1.25% |
| TAK | $14.88 | -1.26% | 47B | 51.29 | $0.29 | +4.05% |
| HLN | $9.63 | -0.52% | 43.6B | 21.39 | $0.45 | +1.82% |
| TEVA | $18.15 | +0.17% | 20.8B | -120.93 | -$0.15 | N/A |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| NBIX | $136.84 | +2.13% | 13.6B | 40.37 | $3.39 | N/A |
| VTRS | $10.41 | -1.33% | 12.1B | -3.55 | -$2.93 | +4.62% |
| RDY | $14.21 | -1.73% | 11.8B | 18.24 | $0.78 | +0.64% |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
Stock Comparison
AKAN vs ZTS Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, ZTS has a market cap of 68.6B. Regarding current trading prices, AKAN is priced at $4.36, while ZTS trades at $154.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas ZTS's P/E ratio is 26.65. In terms of profitability, AKAN's ROE is -0.93%, compared to ZTS's ROE of +0.53%. Regarding short-term risk, AKAN is more volatile compared to ZTS. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check ZTS's competition here
AKAN vs TAK Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, TAK has a market cap of 47B. Regarding current trading prices, AKAN is priced at $4.36, while TAK trades at $14.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas TAK's P/E ratio is 51.29. In terms of profitability, AKAN's ROE is -0.93%, compared to TAK's ROE of +0.02%. Regarding short-term risk, AKAN is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check TAK's competition here
AKAN vs HLN Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, HLN has a market cap of 43.6B. Regarding current trading prices, AKAN is priced at $4.36, while HLN trades at $9.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas HLN's P/E ratio is 21.39. In terms of profitability, AKAN's ROE is -0.93%, compared to HLN's ROE of +0.09%. Regarding short-term risk, AKAN is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check HLN's competition here
AKAN vs TEVA Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, TEVA has a market cap of 20.8B. Regarding current trading prices, AKAN is priced at $4.36, while TEVA trades at $18.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas TEVA's P/E ratio is -120.93. In terms of profitability, AKAN's ROE is -0.93%, compared to TEVA's ROE of -0.03%. Regarding short-term risk, AKAN is more volatile compared to TEVA. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check TEVA's competition here
AKAN vs ITCI Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, AKAN is priced at $4.36, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas ITCI's P/E ratio is -180.64. In terms of profitability, AKAN's ROE is -0.93%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, AKAN is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check ITCI's competition here
AKAN vs NBIX Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, NBIX has a market cap of 13.6B. Regarding current trading prices, AKAN is priced at $4.36, while NBIX trades at $136.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas NBIX's P/E ratio is 40.37. In terms of profitability, AKAN's ROE is -0.93%, compared to NBIX's ROE of +0.13%. Regarding short-term risk, AKAN is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check NBIX's competition here
AKAN vs VTRS Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, VTRS has a market cap of 12.1B. Regarding current trading prices, AKAN is priced at $4.36, while VTRS trades at $10.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas VTRS's P/E ratio is -3.55. In terms of profitability, AKAN's ROE is -0.93%, compared to VTRS's ROE of -0.20%. Regarding short-term risk, AKAN is more volatile compared to VTRS. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check VTRS's competition here
AKAN vs RDY Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, RDY has a market cap of 11.8B. Regarding current trading prices, AKAN is priced at $4.36, while RDY trades at $14.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas RDY's P/E ratio is 18.24. In terms of profitability, AKAN's ROE is -0.93%, compared to RDY's ROE of +0.17%. Regarding short-term risk, AKAN is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check RDY's competition here
AKAN vs CTLT Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, AKAN is priced at $4.36, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas CTLT's P/E ratio is -27.84. In terms of profitability, AKAN's ROE is -0.93%, compared to CTLT's ROE of -0.06%. Regarding short-term risk, AKAN is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check CTLT's competition here
AKAN vs ELAN Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, ELAN has a market cap of 8.9B. Regarding current trading prices, AKAN is priced at $4.36, while ELAN trades at $17.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas ELAN's P/E ratio is 20.35. In terms of profitability, AKAN's ROE is -0.93%, compared to ELAN's ROE of +0.07%. Regarding short-term risk, AKAN is more volatile compared to ELAN. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check ELAN's competition here
AKAN vs RGC Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, RGC has a market cap of 6.7B. Regarding current trading prices, AKAN is priced at $4.36, while RGC trades at $13.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas RGC's P/E ratio is -1355.00. In terms of profitability, AKAN's ROE is -0.93%, compared to RGC's ROE of -0.50%. Regarding short-term risk, AKAN is more volatile compared to RGC. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check RGC's competition here
AKAN vs LNTH Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, LNTH has a market cap of 3.8B. Regarding current trading prices, AKAN is priced at $4.36, while LNTH trades at $55.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas LNTH's P/E ratio is 14.80. In terms of profitability, AKAN's ROE is -0.93%, compared to LNTH's ROE of +0.24%. Regarding short-term risk, AKAN is more volatile compared to LNTH. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check LNTH's competition here
AKAN vs PRGO Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, PRGO has a market cap of 3.3B. Regarding current trading prices, AKAN is priced at $4.36, while PRGO trades at $23.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas PRGO's P/E ratio is -55.16. In terms of profitability, AKAN's ROE is -0.93%, compared to PRGO's ROE of -0.02%. Regarding short-term risk, AKAN is more volatile compared to PRGO. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check PRGO's competition here
AKAN vs INDV Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, INDV has a market cap of 3.1B. Regarding current trading prices, AKAN is priced at $4.36, while INDV trades at $24.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas INDV's P/E ratio is 30.58. In terms of profitability, AKAN's ROE is -0.93%, compared to INDV's ROE of -0.48%. Regarding short-term risk, AKAN is more volatile compared to INDV. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check INDV's competition here
AKAN vs AMRX Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, AMRX has a market cap of 2.9B. Regarding current trading prices, AKAN is priced at $4.36, while AMRX trades at $9.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas AMRX's P/E ratio is 938.00. In terms of profitability, AKAN's ROE is -0.93%, compared to AMRX's ROE of -0.03%. Regarding short-term risk, AKAN is more volatile compared to AMRX. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check AMRX's competition here
AKAN vs HCM Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, HCM has a market cap of 2.7B. Regarding current trading prices, AKAN is priced at $4.36, while HCM trades at $15.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas HCM's P/E ratio is 5.90. In terms of profitability, AKAN's ROE is -0.93%, compared to HCM's ROE of +0.05%. Regarding short-term risk, AKAN is more volatile compared to HCM. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check HCM's competition here
AKAN vs BHC Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, BHC has a market cap of 2.7B. Regarding current trading prices, AKAN is priced at $4.36, while BHC trades at $7.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas BHC's P/E ratio is 28.68. In terms of profitability, AKAN's ROE is -0.93%, compared to BHC's ROE of -0.09%. Regarding short-term risk, AKAN is more volatile compared to BHC. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check BHC's competition here
AKAN vs ALVOW Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, ALVOW has a market cap of 2.6B. Regarding current trading prices, AKAN is priced at $4.36, while ALVOW trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas ALVOW's P/E ratio is N/A. In terms of profitability, AKAN's ROE is -0.93%, compared to ALVOW's ROE of -0.21%. Regarding short-term risk, AKAN is more volatile compared to ALVOW. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check ALVOW's competition here
AKAN vs SUPN Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, SUPN has a market cap of 2.5B. Regarding current trading prices, AKAN is priced at $4.36, while SUPN trades at $44.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas SUPN's P/E ratio is 38.54. In terms of profitability, AKAN's ROE is -0.93%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, AKAN is more volatile compared to SUPN. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check SUPN's competition here
AKAN vs ALVO Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, ALVO has a market cap of 2.5B. Regarding current trading prices, AKAN is priced at $4.36, while ALVO trades at $8.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas ALVO's P/E ratio is 35.30. In terms of profitability, AKAN's ROE is -0.93%, compared to ALVO's ROE of -0.21%. Regarding short-term risk, AKAN is more volatile compared to ALVO. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check ALVO's competition here
AKAN vs DCPH Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, AKAN is priced at $4.36, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas DCPH's P/E ratio is -11.58. In terms of profitability, AKAN's ROE is -0.93%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, AKAN is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check DCPH's competition here
AKAN vs ANIP Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, ANIP has a market cap of 2B. Regarding current trading prices, AKAN is priced at $4.36, while ANIP trades at $91.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas ANIP's P/E ratio is -133.17. In terms of profitability, AKAN's ROE is -0.93%, compared to ANIP's ROE of -0.03%. Regarding short-term risk, AKAN is more volatile compared to ANIP. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check ANIP's competition here
AKAN vs EMBCV Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, AKAN is priced at $4.36, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas EMBCV's P/E ratio is N/A. In terms of profitability, AKAN's ROE is -0.93%, compared to EMBCV's ROE of +0.71%. Regarding short-term risk, AKAN is more volatile compared to EMBCV. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check EMBCV's competition here
AKAN vs BGM Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, BGM has a market cap of 1.6B. Regarding current trading prices, AKAN is priced at $4.36, while BGM trades at $8.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas BGM's P/E ratio is -27.93. In terms of profitability, AKAN's ROE is -0.93%, compared to BGM's ROE of -0.03%. Regarding short-term risk, AKAN is more volatile compared to BGM. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check BGM's competition here
AKAN vs TARO Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, AKAN is priced at $4.36, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas TARO's P/E ratio is 30.05. In terms of profitability, AKAN's ROE is -0.93%, compared to TARO's ROE of +0.03%. Regarding short-term risk, AKAN is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check TARO's competition here
AKAN vs TLRY Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, TLRY has a market cap of 1.6B. Regarding current trading prices, AKAN is priced at $4.36, while TLRY trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas TLRY's P/E ratio is -0.59. In terms of profitability, AKAN's ROE is -0.93%, compared to TLRY's ROE of -0.78%. Regarding short-term risk, AKAN is more volatile compared to TLRY. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check TLRY's competition here
AKAN vs AVDL Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, AVDL has a market cap of 1.4B. Regarding current trading prices, AKAN is priced at $4.36, while AVDL trades at $14.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas AVDL's P/E ratio is -742.50. In terms of profitability, AKAN's ROE is -0.93%, compared to AVDL's ROE of -0.04%. Regarding short-term risk, AKAN is more volatile compared to AVDL. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check AVDL's competition here
AKAN vs HROW Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, HROW has a market cap of 1.4B. Regarding current trading prices, AKAN is priced at $4.36, while HROW trades at $38.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas HROW's P/E ratio is -137.75. In terms of profitability, AKAN's ROE is -0.93%, compared to HROW's ROE of -0.18%. Regarding short-term risk, AKAN is more volatile compared to HROW. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check HROW's competition here
AKAN vs AMPH Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, AMPH has a market cap of 1.4B. Regarding current trading prices, AKAN is priced at $4.36, while AMPH trades at $30.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas AMPH's P/E ratio is 11.36. In terms of profitability, AKAN's ROE is -0.93%, compared to AMPH's ROE of +0.18%. Regarding short-term risk, AKAN is more volatile compared to AMPH. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check AMPH's competition here
AKAN vs PAHC Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, PAHC has a market cap of 1.3B. Regarding current trading prices, AKAN is priced at $4.36, while PAHC trades at $32.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas PAHC's P/E ratio is 41.85. In terms of profitability, AKAN's ROE is -0.93%, compared to PAHC's ROE of +0.12%. Regarding short-term risk, AKAN is more volatile compared to PAHC. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check PAHC's competition here
AKAN vs EVO Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, EVO has a market cap of 1.2B. Regarding current trading prices, AKAN is priced at $4.36, while EVO trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas EVO's P/E ratio is -6.71. In terms of profitability, AKAN's ROE is -0.93%, compared to EVO's ROE of -0.17%. Regarding short-term risk, AKAN is more volatile compared to EVO. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check EVO's competition here
AKAN vs DVAX Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, DVAX has a market cap of 1.2B. Regarding current trading prices, AKAN is priced at $4.36, while DVAX trades at $10.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas DVAX's P/E ratio is -23.20. In terms of profitability, AKAN's ROE is -0.93%, compared to DVAX's ROE of -0.09%. Regarding short-term risk, AKAN is more volatile compared to DVAX. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check DVAX's competition here
AKAN vs COLL Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, COLL has a market cap of 1.2B. Regarding current trading prices, AKAN is priced at $4.36, while COLL trades at $38.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas COLL's P/E ratio is 36.40. In terms of profitability, AKAN's ROE is -0.93%, compared to COLL's ROE of +0.16%. Regarding short-term risk, AKAN is more volatile compared to COLL. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check COLL's competition here
AKAN vs PCRX Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, PCRX has a market cap of 1.2B. Regarding current trading prices, AKAN is priced at $4.36, while PCRX trades at $25.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas PCRX's P/E ratio is -9.45. In terms of profitability, AKAN's ROE is -0.93%, compared to PCRX's ROE of -0.17%. Regarding short-term risk, AKAN is more volatile compared to PCRX. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check PCRX's competition here
AKAN vs CRON Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, CRON has a market cap of 976.5M. Regarding current trading prices, AKAN is priced at $4.36, while CRON trades at $2.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas CRON's P/E ratio is 51.00. In terms of profitability, AKAN's ROE is -0.93%, compared to CRON's ROE of +0.02%. Regarding short-term risk, AKAN is more volatile compared to CRON. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check CRON's competition here
AKAN vs PETQ Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, AKAN is priced at $4.36, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas PETQ's P/E ratio is 83.73. In terms of profitability, AKAN's ROE is -0.93%, compared to PETQ's ROE of +0.12%. Regarding short-term risk, AKAN is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check PETQ's competition here
AKAN vs EMBC Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, EMBC has a market cap of 831.1M. Regarding current trading prices, AKAN is priced at $4.36, while EMBC trades at $14.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas EMBC's P/E ratio is 10.01. In terms of profitability, AKAN's ROE is -0.93%, compared to EMBC's ROE of -0.11%. Regarding short-term risk, AKAN is more volatile compared to EMBC. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check EMBC's competition here
AKAN vs SNDL Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, SNDL has a market cap of 635.8M. Regarding current trading prices, AKAN is priced at $4.36, while SNDL trades at $2.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas SNDL's P/E ratio is -9.15. In terms of profitability, AKAN's ROE is -0.93%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, AKAN is more volatile compared to SNDL. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check SNDL's competition here
AKAN vs ORGO Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, ORGO has a market cap of 611.5M. Regarding current trading prices, AKAN is priced at $4.36, while ORGO trades at $4.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas ORGO's P/E ratio is -34.43. In terms of profitability, AKAN's ROE is -0.93%, compared to ORGO's ROE of -0.03%. Regarding short-term risk, AKAN is more volatile compared to ORGO. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check ORGO's competition here
AKAN vs SIGA Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, SIGA has a market cap of 607.9M. Regarding current trading prices, AKAN is priced at $4.36, while SIGA trades at $8.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas SIGA's P/E ratio is 7.45. In terms of profitability, AKAN's ROE is -0.93%, compared to SIGA's ROE of +0.41%. Regarding short-term risk, AKAN is more volatile compared to SIGA. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check SIGA's competition here
AKAN vs BDSI Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, AKAN is priced at $4.36, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas BDSI's P/E ratio is 6.82. In terms of profitability, AKAN's ROE is -0.93%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, AKAN is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check BDSI's competition here
AKAN vs EOLS Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, EOLS has a market cap of 494.8M. Regarding current trading prices, AKAN is priced at $4.36, while EOLS trades at $7.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas EOLS's P/E ratio is -7.89. In terms of profitability, AKAN's ROE is -0.93%, compared to EOLS's ROE of +17.91%. Regarding short-term risk, AKAN is more volatile compared to EOLS. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check EOLS's competition here
AKAN vs EBS Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, EBS has a market cap of 464.2M. Regarding current trading prices, AKAN is priced at $4.36, while EBS trades at $8.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas EBS's P/E ratio is 3.32. In terms of profitability, AKAN's ROE is -0.93%, compared to EBS's ROE of +0.27%. Regarding short-term risk, AKAN is more volatile compared to EBS. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check EBS's competition here
AKAN vs ESPR Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, ESPR has a market cap of 441.4M. Regarding current trading prices, AKAN is priced at $4.36, while ESPR trades at $2.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas ESPR's P/E ratio is -4.06. In terms of profitability, AKAN's ROE is -0.93%, compared to ESPR's ROE of +0.32%. Regarding short-term risk, AKAN is more volatile compared to ESPR. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check ESPR's competition here
AKAN vs KMDA Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, KMDA has a market cap of 405.4M. Regarding current trading prices, AKAN is priced at $4.36, while KMDA trades at $7.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas KMDA's P/E ratio is 22.03. In terms of profitability, AKAN's ROE is -0.93%, compared to KMDA's ROE of +0.07%. Regarding short-term risk, AKAN is more volatile compared to KMDA. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check KMDA's competition here
AKAN vs ZYBT Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, ZYBT has a market cap of 401.9M. Regarding current trading prices, AKAN is priced at $4.36, while ZYBT trades at $8.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas ZYBT's P/E ratio is 282.67. In terms of profitability, AKAN's ROE is -0.93%, compared to ZYBT's ROE of +0.04%. Regarding short-term risk, AKAN is more volatile compared to ZYBT. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check ZYBT's competition here
AKAN vs AQST Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, AQST has a market cap of 388.9M. Regarding current trading prices, AKAN is priced at $4.36, while AQST trades at $3.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas AQST's P/E ratio is -5.65. In terms of profitability, AKAN's ROE is -0.93%, compared to AQST's ROE of +1.09%. Regarding short-term risk, AKAN is more volatile compared to AQST. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check AQST's competition here
AKAN vs CGC Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, CGC has a market cap of 352.5M. Regarding current trading prices, AKAN is priced at $4.36, while CGC trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas CGC's P/E ratio is -0.48. In terms of profitability, AKAN's ROE is -0.93%, compared to CGC's ROE of -0.99%. Regarding short-term risk, AKAN is more volatile compared to CGC. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check CGC's competition here
AKAN vs ALIM Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, AKAN is priced at $4.36, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas ALIM's P/E ratio is 5.28. In terms of profitability, AKAN's ROE is -0.93%, compared to ALIM's ROE of -0.24%. Regarding short-term risk, AKAN is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check ALIM's competition here
AKAN vs ACB Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, ACB has a market cap of 298.1M. Regarding current trading prices, AKAN is priced at $4.36, while ACB trades at $5.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas ACB's P/E ratio is -132.50. In terms of profitability, AKAN's ROE is -0.93%, compared to ACB's ROE of +0.00%. Regarding short-term risk, AKAN is more volatile compared to ACB. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check ACB's competition here
AKAN vs LFCR Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, LFCR has a market cap of 280.6M. Regarding current trading prices, AKAN is priced at $4.36, while LFCR trades at $7.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas LFCR's P/E ratio is -5.91. In terms of profitability, AKAN's ROE is -0.93%, compared to LFCR's ROE of -2.53%. Regarding short-term risk, AKAN is more volatile compared to LFCR. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check LFCR's competition here
AKAN vs LNDC Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, AKAN is priced at $4.36, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas LNDC's P/E ratio is -4.04. In terms of profitability, AKAN's ROE is -0.93%, compared to LNDC's ROE of -10.27%. Regarding short-term risk, AKAN is more volatile compared to LNDC. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check LNDC's competition here
AKAN vs TKNO Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, TKNO has a market cap of 244.6M. Regarding current trading prices, AKAN is priced at $4.36, while TKNO trades at $4.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas TKNO's P/E ratio is -11.72. In terms of profitability, AKAN's ROE is -0.93%, compared to TKNO's ROE of -0.27%. Regarding short-term risk, AKAN is more volatile compared to TKNO. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check TKNO's competition here
AKAN vs TYHT Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, AKAN is priced at $4.36, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas TYHT's P/E ratio is -1.61. In terms of profitability, AKAN's ROE is -0.93%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, AKAN is more volatile compared to TYHT. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check TYHT's competition here
AKAN vs OGI Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, OGI has a market cap of 220.9M. Regarding current trading prices, AKAN is priced at $4.36, while OGI trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas OGI's P/E ratio is 165.00. In terms of profitability, AKAN's ROE is -0.93%, compared to OGI's ROE of +0.02%. Regarding short-term risk, AKAN is more volatile compared to OGI. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check OGI's competition here
AKAN vs IRWD Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, IRWD has a market cap of 206.3M. Regarding current trading prices, AKAN is priced at $4.36, while IRWD trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas IRWD's P/E ratio is -25.40. In terms of profitability, AKAN's ROE is -0.93%, compared to IRWD's ROE of +0.03%. Regarding short-term risk, AKAN is more volatile compared to IRWD. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check IRWD's competition here
AKAN vs DERM Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, DERM has a market cap of 180.9M. Regarding current trading prices, AKAN is priced at $4.36, while DERM trades at $7.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas DERM's P/E ratio is -20.05. In terms of profitability, AKAN's ROE is -0.93%, compared to DERM's ROE of -0.49%. Regarding short-term risk, AKAN is more volatile compared to DERM. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check DERM's competition here
AKAN vs REPH Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, AKAN is priced at $4.36, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas REPH's P/E ratio is -8.04. In terms of profitability, AKAN's ROE is -0.93%, compared to REPH's ROE of -0.22%. Regarding short-term risk, AKAN is more volatile compared to REPH. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check REPH's competition here
AKAN vs SXTC Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, SXTC has a market cap of 171.7M. Regarding current trading prices, AKAN is priced at $4.36, while SXTC trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas SXTC's P/E ratio is -0.68. In terms of profitability, AKAN's ROE is -0.93%, compared to SXTC's ROE of +0.17%. Regarding short-term risk, AKAN is more volatile compared to SXTC. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check SXTC's competition here
AKAN vs BIOA Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, BIOA has a market cap of 165.3M. Regarding current trading prices, AKAN is priced at $4.36, while BIOA trades at $4.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas BIOA's P/E ratio is -0.68. In terms of profitability, AKAN's ROE is -0.93%, compared to BIOA's ROE of -0.25%. Regarding short-term risk, AKAN is more volatile compared to BIOA. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check BIOA's competition here
AKAN vs THTX Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, THTX has a market cap of 149.4M. Regarding current trading prices, AKAN is priced at $4.36, while THTX trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas THTX's P/E ratio is -17.11. In terms of profitability, AKAN's ROE is -0.93%, compared to THTX's ROE of +0.38%. Regarding short-term risk, AKAN is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check THTX's competition here
AKAN vs SCTL Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, AKAN is priced at $4.36, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas SCTL's P/E ratio is -7.86. In terms of profitability, AKAN's ROE is -0.93%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, AKAN is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check SCTL's competition here
AKAN vs PROC Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, PROC has a market cap of 114M. Regarding current trading prices, AKAN is priced at $4.36, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas PROC's P/E ratio is 1.53. In terms of profitability, AKAN's ROE is -0.93%, compared to PROC's ROE of -2.22%. Regarding short-term risk, AKAN is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check PROC's competition here
AKAN vs OPTN Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, AKAN is priced at $4.36, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas OPTN's P/E ratio is -4.42. In terms of profitability, AKAN's ROE is -0.93%, compared to OPTN's ROE of +0.64%. Regarding short-term risk, AKAN is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check OPTN's competition here
AKAN vs ZOM Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, AKAN is priced at $4.36, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas ZOM's P/E ratio is -1.62. In terms of profitability, AKAN's ROE is -0.93%, compared to ZOM's ROE of -0.52%. Regarding short-term risk, AKAN is more volatile compared to ZOM. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check ZOM's competition here
AKAN vs CRDL Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, CRDL has a market cap of 95M. Regarding current trading prices, AKAN is priced at $4.36, while CRDL trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas CRDL's P/E ratio is -3.29. In terms of profitability, AKAN's ROE is -0.93%, compared to CRDL's ROE of -2.33%. Regarding short-term risk, AKAN is more volatile compared to CRDL. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check CRDL's competition here
AKAN vs INCR Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, INCR has a market cap of 89.9M. Regarding current trading prices, AKAN is priced at $4.36, while INCR trades at $1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas INCR's P/E ratio is -4.02. In terms of profitability, AKAN's ROE is -0.93%, compared to INCR's ROE of -0.15%. Regarding short-term risk, AKAN is more volatile compared to INCR. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check INCR's competition here
AKAN vs GRVI Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, AKAN is priced at $4.36, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas GRVI's P/E ratio is 26.05. In terms of profitability, AKAN's ROE is -0.93%, compared to GRVI's ROE of +0.28%. Regarding short-term risk, AKAN is more volatile compared to GRVI. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check GRVI's competition here
AKAN vs ASRT Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, ASRT has a market cap of 75.1M. Regarding current trading prices, AKAN is priced at $4.36, while ASRT trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas ASRT's P/E ratio is -1.74. In terms of profitability, AKAN's ROE is -0.93%, compared to ASRT's ROE of -0.38%. Regarding short-term risk, AKAN is more volatile compared to ASRT. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check ASRT's competition here
AKAN vs ZYNE Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, AKAN is priced at $4.36, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, AKAN's ROE is -0.93%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, AKAN is more volatile compared to ZYNE. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check ZYNE's competition here
AKAN vs SSIC Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, AKAN is priced at $4.36, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas SSIC's P/E ratio is 11.93. In terms of profitability, AKAN's ROE is -0.93%, compared to SSIC's ROE of +0.09%. Regarding short-term risk, AKAN is more volatile compared to SSIC. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check SSIC's competition here
AKAN vs KALA Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, KALA has a market cap of 65.9M. Regarding current trading prices, AKAN is priced at $4.36, while KALA trades at $9.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas KALA's P/E ratio is -1.57. In terms of profitability, AKAN's ROE is -0.93%, compared to KALA's ROE of -6.86%. Regarding short-term risk, AKAN is more volatile compared to KALA. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check KALA's competition here
AKAN vs IXHL Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, IXHL has a market cap of 65.2M. Regarding current trading prices, AKAN is priced at $4.36, while IXHL trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas IXHL's P/E ratio is -0.58. In terms of profitability, AKAN's ROE is -0.93%, compared to IXHL's ROE of -3.57%. Regarding short-term risk, AKAN is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for AKAN.Check IXHL's competition here
AKAN vs QNTM Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, QNTM has a market cap of 62.3M. Regarding current trading prices, AKAN is priced at $4.36, while QNTM trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas QNTM's P/E ratio is -1.43. In terms of profitability, AKAN's ROE is -0.93%, compared to QNTM's ROE of -2.90%. Regarding short-term risk, AKAN is more volatile compared to QNTM. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check QNTM's competition here
AKAN vs VLNS Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, AKAN is priced at $4.36, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas VLNS's P/E ratio is -1.03. In terms of profitability, AKAN's ROE is -0.93%, compared to VLNS's ROE of N/A. Regarding short-term risk, AKAN is more volatile compared to VLNS. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check VLNS's competition here
AKAN vs DRRX Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, DRRX has a market cap of 59.9M. Regarding current trading prices, AKAN is priced at $4.36, while DRRX trades at $1.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas DRRX's P/E ratio is -4.49. In terms of profitability, AKAN's ROE is -0.93%, compared to DRRX's ROE of -0.71%. Regarding short-term risk, AKAN is more volatile compared to DRRX. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check DRRX's competition here
AKAN vs CPIX Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, CPIX has a market cap of 50.9M. Regarding current trading prices, AKAN is priced at $4.36, while CPIX trades at $3.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas CPIX's P/E ratio is -15.45. In terms of profitability, AKAN's ROE is -0.93%, compared to CPIX's ROE of -0.11%. Regarding short-term risk, AKAN is more volatile compared to CPIX. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check CPIX's competition here
AKAN vs JUPW Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, AKAN is priced at $4.36, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas JUPW's P/E ratio is -2.41. In terms of profitability, AKAN's ROE is -0.93%, compared to JUPW's ROE of -0.32%. Regarding short-term risk, AKAN is more volatile compared to JUPW. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check JUPW's competition here
AKAN vs RMTI Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, RMTI has a market cap of 42.7M. Regarding current trading prices, AKAN is priced at $4.36, while RMTI trades at $1.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas RMTI's P/E ratio is -17.71. In terms of profitability, AKAN's ROE is -0.93%, compared to RMTI's ROE of -0.07%. Regarding short-term risk, AKAN is more volatile compared to RMTI. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check RMTI's competition here
AKAN vs EGRX Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, EGRX has a market cap of 41.4M. Regarding current trading prices, AKAN is priced at $4.36, while EGRX trades at $3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas EGRX's P/E ratio is 3.75. In terms of profitability, AKAN's ROE is -0.93%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, AKAN is more volatile compared to EGRX. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check EGRX's competition here
AKAN vs QLI Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, AKAN is priced at $4.36, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas QLI's P/E ratio is -4.92. In terms of profitability, AKAN's ROE is -0.93%, compared to QLI's ROE of -0.16%. Regarding short-term risk, AKAN is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check QLI's competition here
AKAN vs SCYX Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, SCYX has a market cap of 34.4M. Regarding current trading prices, AKAN is priced at $4.36, while SCYX trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas SCYX's P/E ratio is -2.05. In terms of profitability, AKAN's ROE is -0.93%, compared to SCYX's ROE of -0.37%. Regarding short-term risk, AKAN is more volatile compared to SCYX. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check SCYX's competition here
AKAN vs HEXO Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, AKAN is priced at $4.36, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas HEXO's P/E ratio is -0.26. In terms of profitability, AKAN's ROE is -0.93%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, AKAN is more volatile compared to HEXO. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check HEXO's competition here
AKAN vs COSM Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, COSM has a market cap of 25M. Regarding current trading prices, AKAN is priced at $4.36, while COSM trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas COSM's P/E ratio is -0.83. In terms of profitability, AKAN's ROE is -0.93%, compared to COSM's ROE of -0.55%. Regarding short-term risk, AKAN is more volatile compared to COSM. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check COSM's competition here
AKAN vs CYTH Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, AKAN is priced at $4.36, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas CYTH's P/E ratio is -0.80. In terms of profitability, AKAN's ROE is -0.93%, compared to CYTH's ROE of +3.20%. Regarding short-term risk, AKAN is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check CYTH's competition here
AKAN vs ACRX Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, AKAN is priced at $4.36, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas ACRX's P/E ratio is -0.31. In terms of profitability, AKAN's ROE is -0.93%, compared to ACRX's ROE of -1.51%. Regarding short-term risk, AKAN is more volatile compared to ACRX. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check ACRX's competition here
AKAN vs PRPH Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, PRPH has a market cap of 14.3M. Regarding current trading prices, AKAN is priced at $4.36, while PRPH trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas PRPH's P/E ratio is -0.17. In terms of profitability, AKAN's ROE is -0.93%, compared to PRPH's ROE of -2.30%. Regarding short-term risk, AKAN is more volatile compared to PRPH. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check PRPH's competition here
AKAN vs AYTU Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, AYTU has a market cap of 14.1M. Regarding current trading prices, AKAN is priced at $4.36, while AYTU trades at $2.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas AYTU's P/E ratio is -1.53. In terms of profitability, AKAN's ROE is -0.93%, compared to AYTU's ROE of +0.05%. Regarding short-term risk, AKAN is more volatile compared to AYTU. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check AYTU's competition here
AKAN vs TXMD Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, TXMD has a market cap of 13.1M. Regarding current trading prices, AKAN is priced at $4.36, while TXMD trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas TXMD's P/E ratio is -22.60. In terms of profitability, AKAN's ROE is -0.93%, compared to TXMD's ROE of -0.02%. Regarding short-term risk, AKAN is more volatile compared to TXMD. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check TXMD's competition here
AKAN vs GELS Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, GELS has a market cap of 12.8M. Regarding current trading prices, AKAN is priced at $4.36, while GELS trades at $1.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas GELS's P/E ratio is -3.76. In terms of profitability, AKAN's ROE is -0.93%, compared to GELS's ROE of -0.07%. Regarding short-term risk, AKAN is more volatile compared to GELS. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check GELS's competition here
AKAN vs FLGC Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, FLGC has a market cap of 12.3M. Regarding current trading prices, AKAN is priced at $4.36, while FLGC trades at $22.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas FLGC's P/E ratio is -0.61. In terms of profitability, AKAN's ROE is -0.93%, compared to FLGC's ROE of -2.98%. Regarding short-term risk, AKAN is more volatile compared to FLGC. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check FLGC's competition here
AKAN vs TLPH Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, TLPH has a market cap of 11.4M. Regarding current trading prices, AKAN is priced at $4.36, while TLPH trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas TLPH's P/E ratio is -1.42. In terms of profitability, AKAN's ROE is -0.93%, compared to TLPH's ROE of -1.51%. Regarding short-term risk, AKAN is more volatile compared to TLPH. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check TLPH's competition here
AKAN vs BFRIW Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, BFRIW has a market cap of 10.9M. Regarding current trading prices, AKAN is priced at $4.36, while BFRIW trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas BFRIW's P/E ratio is -0.11. In terms of profitability, AKAN's ROE is -0.93%, compared to BFRIW's ROE of -11.51%. Regarding short-term risk, AKAN is more volatile compared to BFRIW. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check BFRIW's competition here
AKAN vs AGRX Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, AKAN is priced at $4.36, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas AGRX's P/E ratio is -0.89. In terms of profitability, AKAN's ROE is -0.93%, compared to AGRX's ROE of +0.66%. Regarding short-term risk, AKAN is more volatile compared to AGRX. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check AGRX's competition here
AKAN vs BFRI Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, BFRI has a market cap of 9.6M. Regarding current trading prices, AKAN is priced at $4.36, while BFRI trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas BFRI's P/E ratio is -0.49. In terms of profitability, AKAN's ROE is -0.93%, compared to BFRI's ROE of -11.51%. Regarding short-term risk, AKAN is more volatile compared to BFRI. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check BFRI's competition here
AKAN vs EVOK Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, EVOK has a market cap of 8.4M. Regarding current trading prices, AKAN is priced at $4.36, while EVOK trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas EVOK's P/E ratio is -4.33. In terms of profitability, AKAN's ROE is -0.93%, compared to EVOK's ROE of -0.99%. Regarding short-term risk, AKAN is more volatile compared to EVOK. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check EVOK's competition here
AKAN vs NLTX Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, AKAN is priced at $4.36, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas NLTX's P/E ratio is -0.28. In terms of profitability, AKAN's ROE is -0.93%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, AKAN is more volatile compared to NLTX. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check NLTX's competition here
AKAN vs SNOA Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, SNOA has a market cap of 7.9M. Regarding current trading prices, AKAN is priced at $4.36, while SNOA trades at $4.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas SNOA's P/E ratio is -2.18. In terms of profitability, AKAN's ROE is -0.93%, compared to SNOA's ROE of -0.76%. Regarding short-term risk, AKAN is more volatile compared to SNOA. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check SNOA's competition here
AKAN vs LCI Comparison August 2025
AKAN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AKAN stands at 9.9M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, AKAN is priced at $4.36, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AKAN currently has a P/E ratio of -1.39, whereas LCI's P/E ratio is -0.04. In terms of profitability, AKAN's ROE is -0.93%, compared to LCI's ROE of +1.66%. Regarding short-term risk, AKAN is more volatile compared to LCI. This indicates potentially higher risk in terms of short-term price fluctuations for AKAN.Check LCI's competition here